Duties and Responsibilities of a WDA Licence Holder (2026)

Duties of the Licence Holder

A Wholesale Distribution Authorisation (WDA) Licence Holder has a critical role in safeguarding the integrity of  medicines within the supply chain. The Licence Holder is the corporate body that hold the WDA, i.e. any person listed on Companies House. The legal and professional responsibilities attached to a WDA licence go far beyond commercial distribution; they exist to ensure that medicinal products remain safe, effective, and of assured quality from manufacturer to patient.

In the United Kingdom, these responsibilities are defined primarily by the Human Medicines Regulations 2012 and are demonstrated through compliance with the EU Guidelines on Good Distribution Practice (GDP) 2013/c 343/01.

This blog outlines the key duties and responsibilities of a WDA Licence Holder, structured around the core themes of the legislation and GDP guidance.

Legal obligation to comply with GDP

At the heart of the WDA framework is a clear statutory obligation to follow GDP.
The Human Medicines Regulations 2012 state:

“The Licence Holder must comply with the guidelines on good distribution practice.”
(Human Medicines Regulations 2012, regulation 18)

This requirement makes GDP compliance a legal condition of holding a WDA licence, not merely a best-practice expectation. Failure to comply with GDP may therefore result in regulatory enforcement action, including licence suspension or revocation.

The purpose of GDP is articulated in the EU guidance itself:

“Compliance with these Guidelines will ensure control of the distribution chain and consequently maintain the quality and the integrity of medicinal products.”
(EU GDP, Chapter 1 – Quality Management)

Establishing and maintaining a Quality Management System (QMS)

A core responsibility of the WDA Licence Holder is to establish and maintain an effective Quality Management System.

GDP makes clear that quality is not incidental but must be systematically managed:

“A quality system should be developed, implemented and maintained.”
(EU GDP, Chapter 1 – Quality Management)

The QMS must cover all wholesale distribution activities, including procurement, receipt, storage, picking, packing, transport, and supply. This requires documented procedures (SOPs), quality risk management, deviation handling, corrective and preventive actions (CAPA), and management oversight.

The Licence Holder is accountable for ensuring that the QMS is adequately resourced and that it remains effective as operations evolve.

Premises, equipment and environmental controls

The suitability of premises and equipment is a fundamental consideration in wholesale distribution.

The Human Medicines Regulations require regulators to assess:

“the premises on which medicinal products…will be stored” and “the equipment which is available for storing medicinal products on those premises.”
(Human Medicines Regulations 2012, Schedule 2)

Under GDP, premises must be designed and maintained to prevent mix-ups, contamination, and deterioration of products. Environmental conditions must be controlled and monitored:

“Medicinal products should be stored under conditions which assure that their quality is maintained.”
(EU GDP, Chapter 3 – Premises and Equipment)

The WDA holder is responsible for ensuring appropriate temperature monitoring, alarm systems, maintenance, calibration, and segregation of quarantined, returned, or recalled stock.

Personnel and Responsible Person oversight

Wholesale distribution depends on competent personnel operating within a clear organisational structure.

GDP states:

“The management of the distributor should designate a person responsible for GDP compliance.”
(EU GDP, Chapter 2 – Personnel)

This individual, often referred to in the UK as the Responsible Person (RP), must have sufficient authority to ensure compliance and be empowered to make quality-related decisions.

In addition, the Licence Holder must ensure that:

“Personnel should be trained in the requirements of GDP.”
(EU GDP, Chapter 2 – Personnel)

Training must be documented, role-specific, and regularly updated, reinforcing that compliance is an organisational responsibility, not solely the task of one individual. Ensuring there is a culture of compliance throughout the organisation can support assurances that the quality of medicines will not be compromised.  

Procurement and supplier qualification

A WDA Licence Holder must ensure that medicinal products are sourced only from authorised and approved suppliers. GDP requires distributors to control their supply chain through documented procedures:

“Suppliers of medicinal products should be approved and authorised.”
(EU GDP, Chapter 5 – Operations)

This includes verifying licences, maintaining supplier approval records, and conducting due diligence before engaging new suppliers and periodically thereafter. The Licence Holder remains accountable for products procured, even if they are handled or stored by third party services, and you do not have sight of the medicines.

Traceability and record keeping

Traceability is a cornerstone of wholesale distribution.
The Human Medicines Regulations impose specific traceability obligations for certain categories of medicinal products, requiring that:

“The medicinal product and its starting materials can be traced through the sourcing, manufacturing, packaging, storage, transport and delivery.”
(Human Medicines Regulations 2012, regulation 48)

More broadly, GDP requires distributors to maintain comprehensive records:

“Records should be kept either in the form of purchase/sales invoices or on computer or any other form, for each transaction.”
(EU GDP, Chapter 4 – Documentation)

Records must allow full traceability of product, suppliers, and customers, and must be readily available for inspection by competent authorities.

Transportation and distribution controls

Transportation is an extension of storage and must be equally controlled.

GDP is explicit that:

“Medicinal products should be transported in such a way that their quality is maintained.”
(EU GDP, Chapter 9 – Transportation)

The WDA Licence Holder is responsible for ensuring that vehicles, containers, and logistics providers holding a WDA operate under GDP-compliant conditions. Medicinal products must be always transported within their listed storage conditions, and regardless of whether your logistics provider has a WDA or not, it is your responsibility to ensure the goods under your title are transported within their defined limits.

Contracts with external transport providers must clearly define GDP responsibilities, including vehicle cleanliness and security arrangements, and the Licence Holder must retain oversight through audits or performance monitoring.

Please note that the product remains your responsibility until it arrives and is accepted at the final destination.

Returns, recalls and handling of non-conforming products

Returned and recalled products present a particular risk to the supply chain.
GDP requires that returned products are carefully assessed before any decision to reintroduce them into saleable stock, only the Responsible Person is permitted to make this decision:

“An assessment of returned medicinal products should be performed before any approval for resale.”
(EU GDP, Chapter 6 – Complaints, Returns, Suspected Falsified Medicinal Products and Medicinal Product Recalls)

Products suspected of being falsified, damaged, or improperly stored must be segregated and handled according to documented procedures. The Licence Holder must also participate effectively in recall activities, ensuring rapid communication and full traceability, to ensure recalls are communicated to affected customers and suppliers within the documented classification timeframe.

Self-inspections and continual improvement

To ensure ongoing compliance, GDP requires regular self-inspections:

“Self-inspections should be conducted in order to monitor implementation and compliance with GDP principles and to propose corrective measures.”
(EU GDP, Chapter 8 – Self-Inspections)

The WDA Licence Holder must ensure that findings are documented, corrective actions are implemented, and effectiveness is verified. This reinforces the expectation of continual improvement rather than reactive compliance.

 Cooperation with competent authorities

Finally, a WDA Licence Holder must cooperate fully with regulatory authorities.
The Human Medicines Regulations empower regulators to inspect premises, review records, and assess compliance as part of their oversight role. Compliance with inspections and prompt remediation of deficiencies are implicit obligations of holding a licence under the Regulations.

Licence Holder Training

It is strongly recommended that any WDA Licence Holder undertakes full GDP training and specific training relating to their roles and responsibilities as Licence Holder.

GDPTraining.co.uk offer a monthly GDP webinar which is aimed at Responsible Persons and Management and covers all elements of the EU GDP guidelines. In addition, Paradigm Shift Consulting offer an online training course specifically aimed at Licence Holders which details all of the regulations and guidelines which Licence Holders must abide by and adhere to.

Find out more about our training courses here.

The Cost of a Noncompliant Licence Holder

As the Licence Holder, you are legally required to uphold and adhere to the relevant regulations and guidance set out within the Human Medicines Regulations 2012 and the EU GDP guidelines. Failure to adhere to these could result in enforcement action being taken against the individual(s) operating as the Licence Holder, including suspension or revocation of your licence, unlimited fines, referral to other regulatory agencies for enforcement action, or in severe cases, up to 2 years imprisonment.

Conclusion

The duties of a WDA Licence Holder are extensive and continuous.
UK law establishes a clear legal requirement to comply with GDP, while the EU GDP Guidelines provide the operational framework through which that obligation is fulfilled. Together, they place responsibility for quality, traceability, and patient safety squarely on the Licence Holder.

As the legislation states,

“The Licence Holder must comply with the guidelines on good distribution practice”
(HMR 2012, regulation 18),

and as GDP itself emphasises, compliance exists to –

“maintain the quality and the integrity of medicinal products”
(EU GDP, Chapter 1).

These principles define the role of the WDA Licence Holder and underline its critical importance within the medicines supply chain.